198 related articles for article (PubMed ID: 9254514)
1. [Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects].
Bakhteeva VT; Fok EM; Lavrova EA
Vopr Med Khim; 1996; 42(4):301-6. PubMed ID: 9254514
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics of the action of cisplatin and cycloplatam on the rat kidney].
Natochin IuV; Reznik LV; Brovtsyn VK; Ivanov VB; Miazina EM; Chel'tsov PA; Shakhmatova EI
Biull Eksp Biol Med; 1989 Jul; 108(7):52-4. PubMed ID: 2804301
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and new platinum analogs.
Zwelling LA
Cancer Chemother Biol Response Modif; 1987; 9():71-80. PubMed ID: 3079417
[No Abstract] [Full Text] [Related]
4. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
6. [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity].
Koikawa Y
Fukuoka Igaku Zasshi; 1995 Feb; 86(2):31-9. PubMed ID: 7729781
[TBL] [Abstract][Full Text] [Related]
7. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
8. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
[TBL] [Abstract][Full Text] [Related]
9. Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles.
To KK; Au-Yeung SC; Ho YP
Anticancer Drugs; 2006 Jul; 17(6):673-83. PubMed ID: 16917213
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of bischolylglycinatechloro-platinum(II) versus cisplatin on liver regeneration after partial hepatectomy.
Herrera MC; Palomero MF; Macias RI; Serrano MA; Marin JJ
Anticancer Res; 1998; 18(5A):3555-63. PubMed ID: 9858939
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
12. Platinum compounds.
Belani CP; Van Echo DA; Aisner J
Curr Opin Oncol; 1989 Dec; 1(2):186-91. PubMed ID: 2489958
[No Abstract] [Full Text] [Related]
13. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
14. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin and new platinum analogs.
Zwelling LA
Cancer Chemother Biol Response Modif; 1988; 10():64-72. PubMed ID: 3079399
[No Abstract] [Full Text] [Related]
16. Antitumor activity and nephrotoxicity of a novel platinum complex, [1,3-bis(diphenylphosphino)propane](trans-1-dach)platinum(I I) dinitrate.
Baek MS; Rho YS; Jung JC; Chang SG; Nomura M; Miyamoto KJ
Anticancer Res; 1997; 17(2A):955-9. PubMed ID: 9137434
[TBL] [Abstract][Full Text] [Related]
17. The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells.
Legallicier B; Leclere C; Monteil C; Elkaz V; Morin JP; Fillastre JP
Drugs Exp Clin Res; 1996; 22(2):41-50. PubMed ID: 8879978
[TBL] [Abstract][Full Text] [Related]
18. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of platinum cytostatics after cisplatin-related equitoxic dosing to rats.
Amlacher R; Winnefeld K; Schröter H; Hoffmann H
Pharmazie; 1988 Nov; 43(11):798-800. PubMed ID: 3247371
[No Abstract] [Full Text] [Related]
20. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.
Tokunaga Y; Nakashima M; Sasaki H; Tomiyama N; Nakashima MN; Ichikawa M; Kaminogo M; Shibata S
Biol Pharm Bull; 2000 Dec; 23(12):1491-6. PubMed ID: 11145184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
